Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00095524

Enrollment

300

Registered

2004-11-08

Start date

2004-03-31

Completion date

2006-08-31

Last updated

2013-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Weight Change, Psychotic Disorder, Schizoaffective Disorder, Schizophrenia

Keywords

Patient weight change, changes in metabolic status

Brief summary

The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.

Interventions

DRUGAripiprazole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Adult patients diagnosed with schizophrenia or schizoaffective disorder who are currently taking olanzapine.

Design outcomes

Primary

Measure	Time frame
Comparison of weight change from baseline to Week 16 in patients with schizophrenia or schizoaffective disorder treated with aripiprazole or olanzapine	—

Secondary

Measure	Time frame
Assessment of metabolic laboratory measures	—

Countries

Brazil, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026